Edwards Lifesciences (NYSE: EW) and Medtronic (NYSE: MDT) are among the medtech companies praising CMS’s decision to expand Medicare coverage for TAVR to people with asymptomatic severe aortic stenosis. The finalized national coverage decision, published yesterday evening, also removes the evidence development (CED) requirement for symptomatic … [Read more...] about Edwards Lifesciences, Medtronic score CMS win over TAVR
TAVR
Medtronic Evolut Pro TAVR demonstrates positive outcomes in study
Medtronic (NYSE:MDT) this week shared new clinical data supporting its Evolut Pro/Pro+ transcatheter aortic valve replacement (TAVR) system. Findings included cusp overlap technique (COT) outcomes from the Optimize PRO clinical study and pooled analysis looking at Evolut Pro patients showing improvement in paravalvular leak (PVL) over time … [Read more...] about Medtronic Evolut Pro TAVR demonstrates positive outcomes in study
Abbott sees the delivery system as a differentiator for its TAVR
A top Abbott executive explains how the company's FlexNav delivery system could make the Portico TAVR competitive. Abbott is aiming to claw away market share from transcatheter aortic valve replacement pioneers Edwards Lifesciences and Medtronic. The Abbott Park, Illinois–based medtech company in September announced FDA approval of its Portico … [Read more...] about Abbott sees the delivery system as a differentiator for its TAVR
Sapien 3 TAVR offers improved outcomes, reduced cost, Edwards Lifesciences says
Edwards Lifesciences (NYSE:EW) today touted a cost-effectiveness analysis that supports transcatheter aortic valve replacement (TAVR) with the Sapien 3. Irvine, California-based Edwards presented data from the Partner 3 trial during the late-breaking clinical trials at the 33rd Transcatheter Cardiovascular Therapeutics (TCT), the annual … [Read more...] about Sapien 3 TAVR offers improved outcomes, reduced cost, Edwards Lifesciences says
Medtronic touts 5-year study of self-expanding TAVR platform
Medtronic (NYSE:MDT) today presented five-year clinical data for its CoreValve and Evolut transcatheter aortic valve implantation (TAVI) platforms. Fridley, Minnesota-based Medtronic presented results from the Surgical Replacement and Transcatheter Aortic Valve Implantation (SURTAVI) trial at the 33rd Transcatheter Cardiovascular Therapeutics … [Read more...] about Medtronic touts 5-year study of self-expanding TAVR platform
Boston Scientific CEO Mike Mahoney talks Lotus decision, post-COVID outlook
Boston Scientific (NYSE:BSX) made waves this month when it recalled and retired its Lotus TAVR product line. Subsequent layoffs, first in Minnesota, then in Ireland, highlighted the impact of the decision to pull Lotus from the highly competitive market as a result of complexities related to the product delivery system and solely that — as the … [Read more...] about Boston Scientific CEO Mike Mahoney talks Lotus decision, post-COVID outlook
Abbott wins CE Mark for FlexNav delivery system
Abbott (NYSE:ABT) announced today that it won CE Mark approval in Europe for the FlexNav delivery system for its Portico transcatheter aortic valve implantation (TAVI) system. The Abbott Park, Ill.-based company’s FlexNav delivery system is designed to offer another tool for doctors to treat patients requiring a transcatheter aortic valve … [Read more...] about Abbott wins CE Mark for FlexNav delivery system
